Evolution of the Average Target: Veradigm Inc.

Evolution of the Target Price: Veradigm Inc.

Changes in Analyst Recommendations: Veradigm Inc.

d6338317cdf.ysOUp4vwNu4jfPQpPsRO2xK0tt-xotUyugC_V35brDI.j7fN08yDUa97O7JPbZE-6UGM-YDo1pp3-2qJNCoTwVP889Pe44pRoWwlgw~686e5b25e55b4eb78071ec12fecbccad
24-03-19 Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15 MT
24-01-19 RBC Halves Price Target on Veradigm to $11 From $22, Keeps Outperform Rating MT
24-01-03 Barclays Starts Allscripts Healthcare Solutions With Equalweight Rating, $11 Price Target MT
23-12-11 Deutsche Bank Adjusts Veradigm Price Target to $15 From $18, Maintains Buy Rating MT
23-07-06 Argus Research Downgrades Allscripts Healthcare Solutions to Hold From Buy MT
23-06-30 Deutsche Bank Adjusts Allscripts Healthcare Solutions Price Target to $18 From $21, Maintains Buy Rating MT
23-04-12 Stephens Initiates Allscripts Healthcare Solutions at Equalweight With $13 Price Target MT
23-02-01 Piper Sandler Downgrades Veradigm to Neutral From Overweight, Adjusts Price Target to $18.50 From $17 MT
22-11-18 JPMorgan Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $19, Maintains Underweight Rating MT
22-11-09 Goldman Sachs Upgrades Allscripts Healthcare Solutions to Buy From Neutral, Adjusts Price Target to $23 From $22 MT
22-11-07 Deutsche Bank Adjusts Allscripts Healthcare Solutions Price Target to $21 From $20, Maintains Buy Rating MT
22-10-06 Deutsche Bank Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $26, Maintains Buy Rating MT
22-09-16 KeyBanc Initiates Coverage on Allscripts Healthcare Solutions With Sector Weight Rating MT
22-07-12 Goldman Sachs Starts Allscripts Healthcare Solutions at Neutral With $21 Price Target MT
22-06-10 Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $17 From $19, Maintains Neutral Rating MT
22-03-18 Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $22 From $19, Maintains Neutral Rating MT
22-03-04 Deutsche Bank Lifts Allscripts Healthcare Solutions to Buy From Hold, Price Target to $26 From $20 MT
22-03-03 SVB Leerink Adjusts Allscripts Healthcare Solutions' Price Target to $24 from $22, Keeps Outperform Rating MT
22-01-25 SVB Leerink Upgrades Allscripts Healthcare Solutions to Outperform from Market Perform, Adjusts Price Target to $22 from $19 MT
22-01-25 Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $19 From $17, Maintains Neutral Rating MT
21-11-23 Deutsche Bank Adjusts Allscripts Healthcare Solutions PT to $20 From $18, Maintains Hold Rating MT
21-11-08 Canaccord Genuity Adjusts Price Target on Allscripts Healthcare Solutions to $21 From $18, Keeps Buy Rating MT
21-08-06 Allscripts Healthcare : RBC Lifts Price Target on Allscripts Healthcare Solutions to $19 From $17, Maintains Outperform Rating MT
21-05-20 Allscripts Healthcare : Deutsche Bank Adjusts Price Target on Allscripts Healthcare Solutions to $17 From $15, Maintains Hold Rating MT
21-03-02 Allscripts Healthcare : Argus Downgrades Allscripts Healthcare Solutions to Hold From Buy MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- +35.14%
+7.3%
+16.4%
+17.08%
-11.06%
+64.73%
+68.34%
- +50.9%
- - +6.79%
Average +28.40%
Weighted average by Cap. +12.48%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.810USD
Average target price
6.500USD
Spread / Average Target
+35.14%
High Price Target
8.000USD
Spread / Highest target
+66.32%
Low Price Target
5.000USD
Spread / Lowest Target
+3.95%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. MDRX Stock
  4. Consensus Veradigm Inc.